PRO 140: Completed Phase II enrollment

Progenics completed enrollment of 44 early-stage HIV patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 162 or 324 mg of subcutaneous PRO 140 given once weekly or 324 mg of...